Sinphar Pharmaceutical Co (TPE:1734) Research & Development: NT$145 Mil (TTM As of Dec. 2025)


TPE:1734 Sinphar Pharmaceutical Co Ltd TPE:1734
81 GF Score
Price NT$32.00
GF Value NT$33.13
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Sinphar Pharmaceutical Co Research & Development?

Sinphar Pharmaceutical Co TPE:1734 -1.08% 81 Research & Development is NT$145 Mil as of Dec. 2025. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.13 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sinphar Pharmaceutical Co's Research & Development for the three months ended in Dec. 2025 was NT$38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$145 Mil.

Sinphar Pharmaceutical Co  (TPE:1734) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sinphar Pharmaceutical Co Research & Development Related Terms

Sinphar Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co Research & Development Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 511.88 272.16 132.58 151.36 145.37

Sinphar Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.03 29.86 38.00 40.00 37.51
TPE:1734
81GF Score
Sinphar Pharmaceutical Co Ltd TPE:1734
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinphar Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$145 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$145 Mil mean?
Sinphar Pharmaceutical Co (TPE:1734) has a Research & Development of NT$145 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Sinphar Pharmaceutical Co and its competitors.
Is Sinphar Pharmaceutical Co's Research & Development too high?
Sinphar Pharmaceutical Co's current Research & Development is NT$145 Mil. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Research & Development compare to VRTX and REGN?
Sinphar Pharmaceutical Co's Research & Development of NT$145 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current Research & Development is NT$145 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.13, compared to a current price of NT$32.00 — trading 3.4% below its estimated fair value. The current Research & Development is NT$145 Mil. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Research & Development is NT$145 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$32.00 is trading 3.4% below its estimated GF Value™ of NT$33.13. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

  • Research & Development: NT$145 Mil
  • GF Value™: NT$33.13 vs. price of NT$32.00 (3.4% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinphar Pharmaceutical Co Business Description

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score

Get the complete analysis for TPE:1734

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.00
Price
NT$33.13
GF Value